Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers

Author(s): Amol B. Khade, Sidhartha S. Kar, Cinu T. Alummoottil, Ashutosh Tiwari, Mradul Tiwari, Vandana K. Eshwara, Pritesh Bhat, Varadaraj B. Giliyar, Gurupur G. Shenoy*

Journal Name: Medicinal Chemistry

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The well-known antibacterial agent Triclosan (TCL) that targets bacterial enoylacyl protein reductase has been described to inhibit human fatty acid synthase (FASN) via the enoylacyl reductase domain. A Literature survey indicates that TCL is selectively toxic to cancer cells and furthermore might indeed reduce cancer incidence in vivo. A recent study found that TCL inhibits FASN by acting as an allosteric protein-protein interface (PPI) inhibitor. It induces dimer orientation changes that effect in a downstream reorientation of catalytic residues in the NADPH binding site proposing TCL as a viable scaffold to design a superior molecule that might have more inhibitory potential. This unveils tons of potential interaction space to take advantage of future inhibitor design.

Objectives: Synthesis of TCL mimicking novel diphenyl ether derivatives, biological evaluation as potential antiproliferative agents and molecular docking and molecular dynamics simulation studies.

Methods: A series of novel N-(1-(3-hydroxy-4-phenoxyphenyl)-3-oxo-3-phenylpropyl)acetamides (3a-n) and N-(3(3-hydroxy-4phenoxyphenyl)-3-oxo-1-phenylpropyl) acetamides (6a-n) were designed, synthesized, characterized and evaluated against HepG2, A-549, MCF-7 and Vero cell lines. The induction of antiproliferative activity of selected compounds (3d and 6c) was done by AO/EB (acridine orange/ethidium bromide) nuclear staining method, DNA fragmentation study, and cell cycle analysis was performed by flow cytometry. Molecular docking and dynamics simulation study was also performed.

Results: Among the tested compounds, compound 3d was most active (IC50 13.76 ± 0.43 µM) against A-549 cell line. Compounds 3d and 3g were found to be moderately active with IC50 30.56 ± 1.1 µM and 25.05 ± 0.8 µM respectively against MCF-7 cell line. Morphological analysis of A-549 cells treated with 3d and 6c clearly demonstrated the reduction of cell viability and induction of apoptosis. DNA fragmentation was observed as a characteristic of apoptosis in treated cells. Further, cell cycle analysis by flow cytometry confirmed that compounds 3d and 6c significantly arrested the cell cycle at the G0/G1 phase. Molecular docking study demonstrated that these compounds exhibit high affinity for the human fatty acid synthase (hFASN) target. Molecular dynamics simulation study of the most active compound 3d was performed for calculating binding free energies using Molecular Mechanics–Generalized Born Surface Area (MM/GBSA).

Conclusion: Compound 3d (IC50 13.76 ± 0.43 µM) has been identified as a potential lead molecule for anticancer activity against A-549 cells followed by 3l, 6c, and 3g. Thus, the design of diphenyl ether derivatives with enhanced affinity to the binding site of hER may lead to the discovery of potential anticancer agents.

Keywords: Antibacterial agent, cancer, diphenyl ether derivatives, triclosan, dakin-west reaction, human enoyl-acyl carrier protein reductase (hER).

[2]
Stewart, B.W.; Wild, C.P. World Cancer Report; 2014; IARC Publications: France, 2014.
[3]
Foo, J.; Michor, F. Evolution of acquired resistance to anti-cancer therapy. J. Theor. Biol., 2014, 355, 10.
[4]
Sadowski, M.C.; Pouwer, R.H.; Gunter, J.H.; Lubik, A.A.; Quinn, R.J.; Nelson, C.C. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. Oncotarget, 2014, 5(19), 9362.
[5]
Sippel, K.K.H.; Vyas, N.K.N.; Zhang, W.; Sankaran, B.; Quiocho, F.A.F.A. Crystal structure of the human fatty acid synthase enoyl- acyl carrier protein-reductase domain complexed with triclosan reveals allosteric protein-protein interface inhibition. J. Biol. Chem., 2014, 289(48), 33287.
[6]
Bharathkumar, I.; Gurubasavaraj, V.P.; Madhusudhan, N.P.; Viswanathan, B.I.; Sowmya, G.S.; Madhuri, K. Design, synthesis and evaluation of diphenyl ether analogues as antitubercular agents. RSC Advances, 2016, 6, 110571-110582.
[7]
De Schrijver, E.; Brusselmans, K.; Heyns, W.; Verhoeven, G.; Swinnen, J.V. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res., 2003, 63(13), 3799.
[8]
Deepa, P.R.; Vandhana, S.; Muthukumaran, S.; Umashankar, V.; Jayanthi, U.; Krishnakumar, S. Chemical inhibition of fatty acid synthase: Molecular docking analysis and biochemical validation in ocular cancer cells. J. Ocul. Biol. Dis. Infor., 2011, 3(4), 117.
[9]
Liu, X.; Shi, Y.; Giranda, V.L.; Luo, Y. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Mol. Cancer Ther., 2006, 5(3), 494.
[10]
Honkisz, E. Zieba-P.; Dorota, W.; Anna, K. The effect of triclosan on hormone secretion and viability of human choriocarcinoma JEG-3 cells. Reprod. Toxicol., 2012, 34(3), 385-392.
[11]
Maier, T.; Leibundgut, M.; Ban, N. The crystal structure of a mammalian fatty acid synthase. Science (New York, N.Y.),, 2008, 321(5894), 1315.
[12]
Flavin, R.; Peluso, S.; Nguyen, P.; Loda, M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol., 2010, 6(4), 551.
[13]
Honkisz, E.; Zieba, P.D.; Wojtowicz, A.K. The effect of triclosan on hormone secretion and viability of human choriocarcinoma JEG-3 cells. Reprod. Toxicol., 2012, 34(3), 385.
[14]
Gillmore, A.; Lauret, C.; Roberts, S.M. A route to the structure proposed for puetuberosanol and approaches to the natural products marshrin and phebalosin. Tetrahedron, 2003, 59, 4363-4375.
[15]
Talwar, S.; Jagani, H.V.; Nayak, P.G.; Kumar, N.; Kishore, A.; Bansal, P.; Shenoy, R.R.; Nandakumar, K. Toxicological evaluation of terminalia paniculata bark extract and its protective effect against CCl4-induced liver injury in rodents. BMC Complement. Altern. Med., 2013, 13(1), 127.
[16]
Reddy, N.D.; Shoja, M.H.; Jayashree, B.S.; Nayak, P.G.; Kumar, N.; Prasad, V.G.; Pai, K.S.R.; Rao, C.M. Chemico-Biological Interactions In vitro and in vivo evaluation of novel cinnamyl sulfonamide hydroxamate derivative against colon adenocarcinoma. Chemico-Biol. Int., 2015, 233, 81-94.
[17]
Gooch, J.L.; Yee, D. Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Lett., 1999, 144(1), 31-37.
[18]
Kuan, L.; Peng, C.L.; Run, L.; Xing, W. Dual AO/EB Staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med. Sci. Monit. Basic Res., 2015, 21, 15-20.
[19]
Protein Data Bank. RCSB PDB. https://www.rcsb.org/structure/4W9N (Accessed June 20, 2015).
[20]
Small-Molecule Drug Discovery Suite 2015-1, Schrödinger, LLC, New York, NY, 2015. https://www.schrodinger.com/citations/# Maestro (Accessed August 25, 2015).
[21]
Schrödinger Release 2015-1: PrimeX, Schrödinger, LLC, New York, NY, 2015. https://www.schrodinger.com/citations/#Prime (Accessed August 25, 2015).
[22]
Schrödinger Release 2015-1: Glide, Schrödinger, LLC, New York, NY, 2015.. https://www.schrodinger.com/citations/#Glide (Accessed August 25, 2015).
[23]
Schrödinger Release 2015-1: Maestro, Schrödinger, LLC, New York, NY, 2015. https://www.schrodinger.com/citations/#Maestro (Accessed August 27, 2015).
[24]
Schrödinger Release 2015-1: LigPrep, Schrödinger, LLC, New York, NY, 2015. https://www.schrodinger.com/citations/#LigPrep (Accessed August 25, 2015).
[25]
Schrödinger Release 2015-1: Desmond Molecular Dynamics System, D.E. Shaw Research, New York, NY, 2015. Maestro- Desmond Interoperability Tools, Schrödinger, New York, NY, 2015.. https://www.schrodinger.com/citations/#Desmond (Accessed September 3, 2015).
[26]
Cinu, T.A.; Sidhartha, S.K.; Indira, B.; Varadaraj, B.G.; Vishnu, P.S.; Shenoy, G.G. Design, synthesis and evaluation of antitubercular activity of Triclosan analogues. Arab. J. Chem., 2019, 12, 3316-3323.
[27]
Evans, D.A.; Katz, J.L.; West, T.R. Synthesis of diaryl ethers through the copper-promoted arylation of phenols with arylboronic acids. An expedient synthesis of thyroxine. Tetrahedron Lett., 1998, 39(19), 2937.
[28]
Sivaraman, S.; Sullivan, T.J.; Johnson, F.; Novichenok, P.; Cui, G.; Simmerling, C.; Tonge, P.J. Inhibition of the bacterial enoyl reductase fabi by triclosan: A structure-reactivity analysis of fabi inhibition by triclosan analogues. J. Med. Chem., 2004, 47, 509.
[29]
Menendez, J.A.; Colomer, R.; Lupu, R. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol. Rep., 2004, 12(2), 411-422.
[30]
Ruan, Z.; Hua, T.; Xue, Y.; Zhongguo, F. Clinical significance and expression of fatty acid synthase mRNA in lung cancer. Chinese J. lung. Cancer, 2006, 9(6), 502-505.
[31]
Axelsen, J.B.; Lotem, J.; Sachs, L.; Domany, E. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc. Natl. Acad. Sci. USA, 2007, 104(32), 13122-13127.
[32]
Kawasaki, M.; Kuwano, K.; Nakanishi, Y.; Hagimoto, N.; Takayama, K.; Pei, X.H.; Maeyama, T.; Yoshimi, M.; Hara, N. Analysis of Fas and Fas ligand expression and function in lung cancer cell lines. Eur. J. Cancer, 2000, 36(5), 656-663.
[33]
Hellquist, H.B.; Olejnicka, B.; Jadner, M.; Andersson, T.; Sederholm, C. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report. Br. J. Cancer, 1997, 76(2), 175-179.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [256 - 270]
Pages: 15
DOI: 10.2174/1573406415666190306152907
Price: $65

Article Metrics

PDF: 20
HTML: 2